Rationale: Atrial fibrillation (AF) causes atrial-tachycardia remodeling (ATR), with enhanced constitutive acetylcholine-regulated K ؉ current (I KAChC ) contributing to action potential duration shortening and AF promotion. The underlying mechanisms are unknown. Objective: To evaluate the role of protein-kinase C (PKC) isoforms in ATR-induced I KAChC activation. Methods and Results: Cells from ATR-dogs (400-bpm atrial pacing for 1 week) were compared to control dog cells. In vitro tachypaced (TP; 3 Hz) canine atrial cardiomyocytes were compared to parallel 1-Hz paced cells. I KAChC single-channel activity was assessed in cell-attached and cell-free (inside-out) patches. Protein expression was assessed by immunoblot. In vitro TP activated I KAChC , mimicking effects of in vivo ATR. Discrepant effects of PKC activation and inhibition between control and ATR cells suggested isoform-selective effects and altered PKC isoform distribution. Conventional PKC isoforms (cPKC; including PKC␣) inhibited, whereas novel isoforms (including PKC) enhanced, acetylcholine-regulated K ؉ current (I KACh ) in inside-out patches. TP and ATR downregulated PKC␣ (by 33% and 37%, respectively) and caused membrane translocation of PKC, switching PKC predominance to the stimulatory novel isoform. TP increased [Ca 2؉ ] i at 2 hours by 30%, with return to baseline at 24 hours. Buffering [Ca 2؉ ] i during TP with the cell-permeable Ca 2؉ chelator BAPTA-AM (1 mol/L) or inhibiting the Ca 2؉ -dependent protease calpain with PD150606 (20 mol/L) prevented PKC␣ downregulation and TP enhancement of I KAChC . PKC inhibition with a cell-permeable peptide inhibitor suppressed TP/ATR-induced I KAChC activation, whereas cPKC inhibition enhanced I KAChC activity in 1-Hz cells. Conclusions: PKC isoforms differentially modulate I KACh , with conventional Ca 2؉ -dependent isoforms inhibiting and novel isoforms enhancing activity. ATR causes a rate-dependent PKC isoform switch, with Ca 2؉ /calpaindependent downregulation of inhibitory PKC␣ and membrane translocation of stimulatory PKC, enhancing I KAChC . These findings provide novel insights into mechanisms underlying I KAChC dysregulation in AF. (Circ Res.
A trial fibrillation (AF), the most common sustained cardiac arrhythmia, leads to atrial tachycardia-induced remodeling (ATR) that promotes AF (AF begets AF). 1 Atrial cardiomyocytes from chronic AF patients or atrialtachypaced dogs exhibit an agonist-independent inward rectifier K ϩ current with properties of the muscarinic cholinoceptor-activated K ϩ current I KACh . [2] [3] [4] [5] Inhibition of this constitutive current (I KAChC ) with the selective Kir3 channel blocker tertiapin reverses ATR-induced action potential duration abbreviation and AF promotion. 3, 4 Enhanced inward rectifier currents are particularly effective in stabilizing and accelerating atrial rotors because, in addition to reducing action potential duration, they hyperpolarize atrial cardiomyocytes and remove voltagedependent I Na inactivation. 6 The molecular basis of ATR-induced I KACh activation is poorly understood. Increased receptor-independent dissociation of G␣ and G␤␥ subunits does not appear to be involved. 3 Studies suggest that agonist-independent I KAch activation requires ATP, [7] [8] [9] pointing to the potential involvement of PKs. Indirect evidence suggests that in AF patients, the isoform of protein kinase C (PKC) may contribute to I KAChC activation. 10 The present study aimed to investigate the molecular basis of ATR-induced I KAChC channel activation in a dog model.
Methods

Animal Model
A total of 100 mongrel dogs (20 -36 kg) were divided into control and ATR groups (including both preliminary studies and work presented in the article). Animal care procedures followed National Institutes of Health guidelines (publication 85-23, revised 1996) and were approved by the Animal Research Ethics Committee of the Montreal Heart Institute. The animal model was prepared as previously described in detail. 11 Briefly, the atrioventricular node was ablated by radiofrequency-application. The right ventricle was paced at 80 bpm and the right atrium was paced at 400 bpm for 7 days. Open chest study was performed as previously described. 12 On study days, dogs were anesthetized (morphine 2 mg ⅐ kg Ϫ1 subcutaneous, ␣-chloralose 120 mg ⅐ kg Ϫ1 intravenous load, 29.25 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 infusion) and mechanically ventilated. Right atrial effective refractory period was measured at basic cycle lengths of 150, 200, 250, 300, and 360 ms with 10 basic stimuli (S1) and a second stimulus (S2) with 5-ms decrements (all pulses twice-threshold, 2 ms). AF (irregular atrial rhythm Ͼ400 bpm) was induced with 1-to 10second atrial burst pacing (10 -20 Hz, 4ϫthreshold, 2-ms pulses).
Mean AF duration was determined in each dog based on 10 AF inductions for AF Ͻ5 minutes and five inductions for 5 to 30 minutes of AF. AF Ͼ30 minutes was considered sustained; cardioversion was not performed and electrophysiological assessment was terminated (Online Table I shows in vivo hemodynamic and electrophysiological data, available at http://circres.ahajournals.org).
Atrial Cardiomyocyte Isolation
Hearts and adjacent lung tissues were excised via a left thoracotomy and immersed in oxygenated Tyrode solution (mmol/L): NaCl, 136; KCl, 5.4; CaCl 2 , 2; MgCl 2 , 1; NaH 2 PO 4 , 0.33; glucose, 10; and HEPES, 5 (pH 7.4, NaOH). Left atrial (LA) cardiomyocytes were isolated as previously described. 3 Briefly, the proximal left circumflex coronary artery was cannulated and the LA was perfused with Ca 2ϩ -free Tyrode solution containing collagenase (100 U ⅐ mL Ϫ1 , Worthington type II). The cells were then either kept for immediate electrophysiology studies in storage solution (KCl 20, KH 2 PO 4 10, glucose 25, potassium glutamate 70, ␤-hydroxybutyric acid 10, taurine 20, EGTA 10, albumin 0.1% mannitol 40; pH 7.4, KOH) at 4°C or kept at 37°C in culture medium (M199 medium supplemented with 1% insulin-transferrin-selenium and 1% penicillin/streptomycin) for in vitro tachypacing. Cell aliquots were also snap-frozen for subsequent biochemical studies.
Culture and Tachystimulation
Freshly isolated LA cardiomyocytes from control animals were plated onto laminin-coated (20 g/mL) 4-well culture dishes (Nunc) and maintained at 37°C, 95% O 2 /5% CO 2 . After 2-hour incubation, dead and unattached cardiomyocytes were removed and fresh medium was added. Cells were then paced at 1 or 3 Hz (studied in parallel for all experimental series) for 2 or 24 hours with squarewave 5-ms pulses. In some experiments, 1 mol/L BAPTA-AM or 20 mol/L PD150606 13 were added to the culture medium during 24-hour pacing or 10 mol/L PKC peptide inhibitor (-V1-2) or conventional PKC (cPKC) peptide inhibitor (␤-C2-4) 14,15 for 1 hour before electrophysiological recording were used. After cell culture/ pacing, cells were subjected to electrophysiological study or fastfrozen for subsequent biochemical study.
Single-Channel Recording
Single-channel currents were recorded in cell-attached and inside-out configurations (Axopatch 200A; Axon). 16 Patch pipettes were prepared from 1.0-mm outside iameter borosilicate glass (Sutter Instruments), coated at the tip with Sylgard, and fire-polished with a microforge. When filled with pipette solution (mmol/L: KCl, 145; MgCl 2 , 1; CaCl 2 , 2; HEPES, 5; pH 7.4, KOH), tip resistances were approximately 8 to 10 megohm and approximately 3 to 4 megohm for cell-attached and inside-out configurations, respectively.
Bath solutions for cell-attached patch studies contained (mmol/L: NaCl, 120; KCl, 20; MgCl 2 , 1; CaCl 2 , 2; glucose, 10; HEPES, 10, pH 7.4, NaOH). Bath (intracellular) solutions for inside-out studies contained (mmol/L) KCl 145, MgCl 2 2 EGTA 2, and HEPES 5 (pH 7.4, Tris). Inside-out configuration was confirmed by: (1) persistence of gigaseal after membrane excision; (2) sporadic I KACh openings;
(3) inhibition of ATP-sensitive channels by ATP; and (4) reactivation of I KACh channels by bath application of ATP and GTP or GTP␥S. I KACh rundown in inside-out patches was limited by adding (mmol/L) fluoride 5, vanadate 0.1, and pyrophosphate 10 to bath solutions. 8, 17, 18 All recordings were performed at room temperature. Singlechannel activity was recorded with previously described detailed methods 16 while holding at Ϫ100 mV. Electric noise was reduced by low-pass filtering at 1 kHz. ISO-2 software (MFK) was used for data acquisition and analysis. 5
Single-Channel Analysis
Data were digitized at 10 kHz. Amplitude and kinetic analyses were performed after leak current subtraction. Amplitude-histograms were 
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Drugs
Chemicals were obtained from Sigma Chemicals unless otherwise indicated. Stock solutions of bisindolylmaleimide-I (0.1 mmol/L; Merck), diacylglycerol-kinase inhibitor-I (R59022; 1 mmol/L), PD150606 (20 mmol/L), carbachol (CCh; 10 mmol/L), phenylephrine (1 mmol/L), BAPTA-AM (1 mmol/L), and phorbol-12-myristate-13-acetate (PMA; 0.1 mmol/L) were stored at Ϫ20°C until use.
Purified PKC isoforms (␣, ␤I, ␤II, ␦, and isoforms) were obtained from Cell Signaling. Stock solutions of PKC␣, PKC␤I, PKC␤II, PKC␦, and PKC (110, 217, 120, 100, and 100 g/L, respectively) were prepared in 5-mol/L aliquots and stored at Ϫ80°C until use. PKCs were activated by 1,2-diacyl-sn-glycero-3phospho-L-serine solution (PS) and 1,2-dioleoyl-sn-glycerol (diacylglycerol [DAG] analog) before usage. Stock solutions of PS (10 mg/mL) and 1,2-dioleoyl-sn-glycerol (2 mg/mL) were aliquoted and kept at Ϫ20°C. Stock solutions of Na 2 GTP (0.1 mmol/L), Mg 2 ATP (3 mmol/L), or GTP␥S (0.1 mmol/L) were prepared in 10-L aliquots and stored at Ϫ20°C.
Cell-permeable myristoylated cPKC peptide inhibitor (␤-C2-4, SLNPEWNET) and a myristoylated scrambled cPKC scrambled control peptide (␤-C2-4scr, WNPESLNT) were synthesized at Sheldon Biotechnology Center of McGill University. Cell-permeable myristoylated PKC peptide inhibitor (-V1-2scr, EAVSLKPT) and a myristoylated scrambled PKC control (-V1-2scr, LSETKPAV) were synthesized and obtained from AnaSpec. 14, 15, 20 
Calcium Transients
Isolated cardiomyocytes were incubated with Indo-1 AM and pluronic F-127 (5 mol/L and 100 mol/L; Invitrogen) for 5 minutes and then superfused with Tyrode solution containing 1.8 mmol/L Ca 2ϩ for 10 minutes (35°C) to allow intracellular de-esterification. Indo-1 was excited with ultraviolet light (340 nm), measured through 10 m aperture, was measured following separation through 400and 500-nm filters. Background fluorescence was cancelled by adjusting the filters to 0 over a cell clear field. The fluorescence ratio (R400/500) was digitized and converted to [Ca 2ϩ ] i . Cardiomyocytes were electrically paced by 10-ms pulses at voltage 1.5-times threshold as previously described. 21
Immunoblots: Protein Extraction
Freshly isolated LA-cardiomyocytes were pelleted, fast-frozen in liquid nitrogen, and homogenized in an extraction buffer containing Tris 25 mmol/L, EDTA 5 mmol/L, EGTA 5 mmol/L, NaCl 150 mmol/L, NaF 20 mmol/L, Na 3 VO 4 0.2 mmol/L, ␤-glycerophosphate 20 mmol/L, PMSF 0.5 mmol/L, leupeptin 25 g/mL, aprotinin 10 g/mL, pepstatin 1 g/mL, microcystin-LR 1 mol/L, and TritonX-100 1% (pH 7.34, HCl). After 30-minute incubation, homogenized samples were centrifuged (3000 rpm, 10 minutes) to pellet debris and nuclei. Supernatant was collected and protein concentration was assessed with Bradford assay (Biorad). All steps were performed on ice at 4°C to 5°C.
Preparation of Cytosolic and Particulate Fractions
LA cardiomyocytes were pelleted and fast-frozen immediately after isolation. Cells were disrupted and homogenized using a Polytron device in 1 mL of ice-cold extraction buffer-A containing (mmol/L):
HEPES, 20 (pHϭ7.5); EDTA, 5; EGTA, 5; NaF, 20; Na 3 VO 4 , 0.2; ␤-glycerophosphate, 20; benzamidine, 10; AEBSF, 0.5; leupeptin, 25 g/mL; and DTT, 5. Homogenates were centrifuged (48 000 rpm, 30 minutes). The supernatant corresponding to the cytosolic fraction was collected. The pellet was resuspended in buffer-A supplemented with 1% TritonX-100 (volume/volume) and incubated for 30 minutes on ice. Ultracentrifugation was again performed at 48 000 rpm. This second supernatant (particulate fraction) containing detergentsoluble proteins was collected.
Protein Separation and Determination
Protein samples (50 g) were separated with SDS-PAGE on 8% (weight/volume) polyacrylamide gels and transferred electrophoretically onto polyvinylidene fluoride membranes. Membranes were blocked in phosphate-buffered saline solution containing 0.05% (volume/volume) Tween-20 and 5% (weight/volume) nonfat dried milk were incubated overnight at 4°C with primary antibodies diluted in phosphate-buffered saline containing 0.05% Tween-20 and 1% nonfat dried milk. After washing with phosphate-buffered saline Tween solution/1% nonfat dried milk, membranes were hybridized with horseradish peroxidase-conjugated secondary antibody. Immunoreactive bands were detected by enhanced chemiluminescence with BioMax MS films. Protein quantification was performed with Quantity-One software (Biorad) and expressed relative to GAPDH staining for the same samples on the same gels. For membrane localization experiments, the intensity of the cytosolic and particulate (membrane) immunoreactive bands were determined and normalized to the sum of their intensity (total content) for a specific sample. Data are expressed as percentages of total immunoreactivity.
Antibodies
Primary antibodies (1/2000) included polyclonal rabbit anti-PKC␣ (2056) and rabbit monoclonal anti-PKC (2683) from Cell Signaling, polyclonal rabbit anti-PKC␤I (AB4132, ABCAM), polyclonal rabbit anti-PKC␦ (sc-937; Santa Cruz), and monoclonal mouse anti-GAPDH (10R-G109a; Fitzgerald). HRP-conjugated AffiniPure goat antirabbit IgG (111-035-144) and Affinipure donkey antimouse IgG (715-035-151) from Jackson ImmunoResearch were used as secondary antibodies.
Statistical Analysis
Single comparisons between group means were performed by Student t test. Multiple group comparisons were obtained with one-way analysis of variance and Bonferroni-corrected t tests. Data are expressed as meanϮstandard error of the mean. PϽ0.05 was considered statistically significant. Throughout the article, n/N refers to the number of myocytes/dogs.
Results
Constitutively Active I KACh Channels
Online Figure IA shows typical cell-attached singlechannel recordings. In the absence of cholinergic stimulation, constitutive I KACh openings (I KAChC ) occurred only sporadically in control cardiomyocytes. I KAChC openings were much more frequent in ATR cells. ATR did not affect single-channel conductance (Online Figure IB 
Inside-Out Patches and I KAChC Phosphorylation Dependence
After excision of the patch and formation of the inside-out configuration, constitutive I KAChC activity of ATR cardiomyocytes was strongly reduced (Ϫ93.8%Ϯ1.7%, nϭ16/4; Figure 1A , middle panel) to a level not significantly different from control cardiomyocytes, pointing to contribution of a cytosolic factor to ATR-associated I KAChC increase. Under these conditions, the application of ATP and GTP (0.1 mol/L and 3 mmol/L, respectively) was insufficient to restore open probabilities ( Figure 1A , right panel) to levels seen in cell-attached configurations. Nevertheless, a statistically significant difference between control and ATR re-emerged, pointing to a role for channel phosphorylation in upregulation of constitutive function by ATR.
Previous studies of agonist-activated I KACh revealed that inhibition of phosphatases is necessary to prevent run-down in cell-free inside-out-patches. 8, 17, 18 In addition, indirect evidence suggests that in AF patients PKC channel phosphorylation may contribute to constitutive I KACh . 10 To assess the contribution of channel phosphorylation, we added phosphatase inhibitors (fluoride, vanadate, and pyrophosphate) 8, 17, 18 to the intracellular side (bath) solution ( Figure 1B 
PKC-Dependent Regulation of I KAChC in Control and ATR Cardiomyocytes
Physiologically, PKC is activated by stimulation of G␣ qcoupled receptors that activate phospholipase C. Phospholipase C hydrolyzes PIP 2 into inositol trisphosphate and DAG, which directly activates PKC. [22] [23] [24] [25] To control for possible time-dependent changes in I KAChC , all experiments involving pharmacological interventions included timematched controls for comparison. To study the effect of PKC on I KAChC , we activated PKC by PMA (0.1 mol/L), which mimics the action of DAG and nonselectively activates conventional as well as novel PKC isoforms. Consistent with previous studies showing that PKC-mediated I KACh phosphorylation decreases I KACh activity, 26 PKC activation decreased I KAChC in control cells (Figure 2A Figure 2B ) also had distinct effects on ATR (significant reduction in open probability) versus controls (no change). These data suggest differential regulation of I KAChC by PKC in control versus ATR. 
Isoform-Selective PKC Regulation of I KACh
The PKC family contains many isoforms, including conventional isoforms (conventional PKCs [cPKCs]), which are activated by Ca 2ϩ and DAG, and novel isoforms (novel PKCs [nPKCs]), which require DAG, but not Ca 2ϩ , for activation. 25 To dissect the effects of conventional versus novel isoforms, we applied recombinant isoforms of cPKCs and nPKCs to the intracellular membrane side of I KACh channels in inside-out cell-free patches. GTP␥S (100 mol/L) was added to the bath to augment I KAChC in control conditions to a level at which inhibitory effects could be appreciated (Figure 3 ). Application of conventional PKC isoforms (␣, ␤I, and ␤II) to excise inside-out patches significantly reduced I KACh in both control ( Figure 3A 26, 27 Control experiments with scrambled PKC␣ and PKC showed no effect (Online Figure IV) .
Tachycardia-Induced PKC Isoform Protein Expression Changes
The results described indicate that cPKC isoforms inhibit, whereas nPKC isoforms increase, I KACh . In control cardiomyocytes, the cPKC (inhibitory) phenotype seems to predominate, whereas in ATR the balance is shifted, with stimulatory effects of nPKC isoforms enhancing constitutive I KACh activity. We therefore compared PKC isoform expression in control versus ATR to determine whether the changes in function may have a basis in altered isoform expression. Figure 4A shows representative immunoblots and densitometric analyses of PKC isoform expression in isolated LA cardiomyocytes. The results show 37% lower expression levels for PKC␣, but unchanged expression of other PKC isoforms, in ATR. These data suggest that reduced PKC␣ expression may underlie the reduced cPKC role in ATR, but do not provide an explanation for the apparently increased effects of nPKCs. We wondered whether changes in subcellular PKC distribution could contribute to the changed PKC isoform response in ATR, because PKC translocation to the membrane accompanies activation. 28 We therefore performed immunoblot experiments on separated cytosolic and particulate (membrane) fractions from LA cardiomyocytes ( Figure  4B ). The relative expression of PKC␣, PKC␤I, and PKC␦ in membrane and cytosolic fractions was not significantly altered by ATR. However, ATR increased the relative membrane expression of PKC, pointing to translocation of PKC from the cytosol. Because membrane translocation is needed for PKC phosphorylation of membrane proteins, this finding may explain the predominance of the nPKC (stimulatory) phenotype in ATR cardiomyocytes.
In vitro tachypacing activated I KAChC (Figure 5A ), mimicking the effects of ATR (Online Figures I and II) . We analyzed the PKC isoform expression changes associated with ATR in vivo and found that similar changes occur with in vitro LA cardiomyocyte tachypacing: total PKC␣ expression is downregulated with no change in PKC expression ( Figure 5B ), whereas PKC shows membrane redistribution and PKC␣ cytosolic/membrane portioning is unchanged (Figure 5C ). Many manipulations required to further study the mechanisms of I KAChC activation are impossible in vivo but feasible in the in vitro tachypaced system, which we therefore exploited.
Role of Tachycardia and Ca 2؉ Loading
Cell tachycardia induces atrial remodeling, with cellular Ca 2ϩ loading implicated in several key signaling-pathways. 21, 29 We examined intracellular Ca 2ϩ ([Ca 2ϩ ] i ) changes in our tachypaced cardiomyocytes and observed significant transient increases ( Figure 6A, B) , as previously reported. 21 We therefore examined the role of increases in [Ca 2ϩ ] i in mediating tachypacing effects on I KAChC . Increasing cell Ca 2ϩ loading by doubling the extracellular [Ca 2ϩ ] during the 24-hour pacing period activated I KAChC in 1-Hz paced cells, mimicking the effects of ATR ( Figure 6C ). Buffering [Ca 2ϩ ] i with the cell-permeable buffer BAPTA-AM during tachypacing suppressed I KAChC activation ( Figure 6D ) and prevented PKC␣ downregulation ( Figure 6E ), but failed to prevent increased PKC membrane localization ( Figure 6F ). Calpain is a Ca 2ϩ -activated enzyme that cleaves cell proteins and can mediate effects of ATR. 13, 30 Inclusion of the cell-permeable highly selective calpain inhibitor PD150606 31 attenuated I KAChC activation ( Figure 6G ) and prevented PKC␣ downregulation ( Figure 6H ) with cell tachypacing, pointing to calpain as a possible mediator of tachycardia-induced reductions in PKC␣ expression.
Effects of PKC Isoform-Specific Inhibition
The experiments described suggest that tachycardia activates I KAChC by suppressing cPKC inhibiting effects and by enhancing nPKC activating effects on channel open probability. To assess the role of these isoforms more directly, we applied membrane-permeable isoform-selective peptide inhibitors, myristoylated forms of the cPKC inhibitor peptide ␤-C2-4 and PKC inhibitor peptide -V1-2, 14,15 both during the last hour of pacing and in the bath. The cPKC inhibitor peptide significantly increased I KAChC activity in 1-Hz paced cells, consistent with a tonic inhibitory influence of PKC␣, but had little effect on 3-Hz paced cells, consistent with PKC␣ downregulation (Figure 7A, left) . However, the PKC inhib- itor peptide did not significantly affect I KAChC in 1-Hz paced cells, but suppressed I KAChC in 3-Hz paced cells ( Figure 7A , right). Corresponding effects were observed in cells isolated from control and ATR dogs ( Figure 7B) . These experiments confirm directly the predominant influence on I KAChC of cPKC-mediated inhibition under control conditions and of PKC-mediated stimulation with ATR.
We previously reported that phenylephrine inhibits I KAChC by a PKC-dependent mechanism. 23 We exposed canine cardiomyocytes to maximally effective phenylephrine concentrations (1 mmol/L) and assessed the effect in the absence and presence of the cPKC inhibitory peptide ␤-C2-4. In the absence of cholinergic stimulation, I KAChC open probability was very low and, even though mean P o was smaller after phenylephrine (Online Figure VA) , no statistically significant decrease was seen. After the addition of carbachol to activate I KACh , clear statistically significant P o decreases were seen with phenylephrine (Online Figure VB) . In both situations, when phenylephrine was superfused in the presence of ␤-C2-4, no significant change was seen compared to results with ␤-C2-4 alone, indicating that the effects of phenylephrine are attributable to conventional PKC isoform activation.
Discussion
Studies in animal models and atrial cardiomyocytes from AF patients suggest that sustained rapid atrial activation increases the function of a constitutively active form of I KACh . [2] [3] [4] [5] Because increased inward rectifier currents like I K1 and I KACh abbreviate atrial action potential duration and remove Na ϩ current inactivation, they stabilize and accelerate highfrequency atrial reentrant sources. 6 There is experimental evidence that enhanced constitutive I KACh activity contributes substantially to the maintenance of tachyarrhythmias in ATRremodeled atria, 4 and a highly selective I KACh inhibitor suppresses AF in ATR hearts. 32 In this study, we show for the first time to our knowledge that novel PKC isoforms activate I KACh , which is in contrast to the well-known inhibitory PKC effect 26, 27 that we show to be attributable to conventional PKC isoforms. We also found that changes in the balance between the effects of PKC isoforms contribute to the increased constitutive I KACh activity of ATR remodeled atrial cardiomyocytes: under control conditions, the cPKC (inhibitory) phenotype predominates, whereas in ATR the nPKC (stimulatory) phenotype prevails. At the molecular level, reduced expression of the cPKC isoform PKC␣ and increased membrane localization of the nPKC isoform PKC appear to underlie the altered cPKC/ nPKC balance in ATR. Isolated cell tachypacing results indicate that rapid cell firing per se is enough to alter PKC isoform balance and activate I KAChC , and that cellular Ca 2ϩ loading is a key mediator, acting primarily by downregulating PKC␣ expression.
Comparison With Previous Studies of Constitutive I KACh and Its Regulation
It is now well-established that ATR is associated with increased basal inward rectifier current in the absence of muscarinic receptor agonists. [33] [34] [35] [36] [37] Although this change was initially attributed to upregulation of the background inward rectifier I K1 , more recent studies have shown a significant contribution of an inward rectifier current (I KAChC ) with properties of type 2 muscarinic-cholinoreceptor-dependent I KACh that is constitutively active in the absence of agonists. [2] [3] [4] Consistent with previous work, 5 we found here that tachycardia-induced enhancement of I KAChC is related to Little is known about the molecular control of constitutive I KACh activity in atrial cardiomyocytes. The similar changes in ionic current and single-channel properties of I KAChC in human chronic AF and in the ATR dog model suggest a common molecular basis. [2] [3] [4] [5] The complex regulation of I KACh points to several possible mechanisms that could contribute to the development of constitutive activity. G␤␥ subunits activate I KACh channels by strengthening the interaction of PIP 2 with the channel subunits. 18 In addition, development of constitutive I KACh activity in Kir3-overexpressing Xenopus oocytes is dependent on ␤␥ subunits. 38 -40 However, raterelated constitutive I KACh activity occurs independently of changes in muscarinic cholinoceptor expression and the dissociation of G␣ and G␤␥ subunits. 2, 3 Accordingly, in the presence of phosphatase inhibitors, I KAChC was only slightly reduced after inside-out patch formation and washout of ATP and GTP ( Figure 1B) , which are necessary for G-protein dissociation.
Because activation of I KACh requires ATP, 9 modified phosphorylation-dependent channel regulation could contribute to constitutive I KACh activity. Supporting this idea, we found that in inside-out patches constitutive activity in the absence of exogenous ATP and GTP was only observed after inhibition of protein phosphatases (Figure 1 ). Previous publications from our group showed that ␤ 1 -adrenoceptor-mediated activation of PKA increases constitutive I KACh . 23 Voigt et al 10 compared the effect on I KAChC of inhibiting CaMKII, PKA, PKC, and PKG in cardiomyocytes from sinus rhythm versus AF patients. The only differential effect observed was that of PKC inhibition, which produced greater effects in AF patient than in sinus rhythm patient cells. Previous studies in expression systems, 26, 41 neonatal rat cardiomyocytes, 27 and canine atrial cardiomyocytes 23 showed inhibitory effects of PKC phosphorylation on I KACh channels, contrasting with the indirect evidence for increased I KACh associated with PKC activation in human atrial cardiomyocytes. Our findings indicate that this discrepancy is attributable to differential expression of cPKC and nPKC isoforms, which we found to exert divergent effects on I KACh activity.
Novel Findings and Potential Significance
The present study constitutes the first detailed assessment of the differential molecular regulation of constitutive I KACh channel function in remodeled atria. Figure 8 provides a schematic representation of our principal findings. We noted that the upregulation of constitutive activity is critically dependent on channel phosphorylation, as evidenced by a requirement for ATP/GTP or protein phosphatase inhibition to reproduce ATR activation in cell-free inside-out membrane-patches. We also report for the first time to our knowledge differential regulation of I KACh by distinct classes of PKC isoforms. Furthermore, we found a role for this differential regulation in a disease paradigm: increased con-stitutive I KACh activity in AF-related atrial remodeling. Because PKC regulates a wide variety of cardiac functions, 42, 43 these findings have potential implications for the molecular regulation of cardiac physiology over a broader range of conditions. Conventional PKC upregulation is important in a variety of ventricular remodeling paradigms, and PKC␣ appears to play an important role in the pathophysiology of heart failure. 44 The downregulation of PKC␣ that we noted with AF-associated ATR may be an autoprotective response, contributing to the adaptive atrial gene expression program evolution seen with ATR in contrast to the changes seen with heart failure. 45 Our findings illuminate previous observations regarding I KAChC Figure 2B . This observation suggested that PKC promotes basal I KACh opening in AF, opposite to the well-recognized inhibitory effect of PKC. 26, 27 Our finding of ATR-induced altered PKC isoform balance, with reduced cPKC inhibition and enhanced nPKC-stimulation, explains the apparent contradiction between the Voigt observations and the previous literature. We also elucidated the underlying molecular basis by showing reduced PKC␣ expression and increased PKC membrane localization in ATR, demonstrated that these effects are attributable to rapid atrial activity per se, and showed that PKC␣ downregulation likely results from tachycardia-induced Ca 2ϩ loading and calpain activation.
I KAChC enhancement in AF has emerged as a potentially interesting therapeutic target. 46 Whereas direct blockade of the I KACh channel pore can suppress I KAChC , off-target effects on I KACh channels in the sinoatrial node and peripheral tissues (eg, gastrointestinal tract, genitourinary system) may limit the value of this approach. 46 An improved understanding of the molecular basis for I KAChC upregulation in AF-related pathology might allow for more specific targeting of the upregulated current. Developing approaches to inhibit PKC and to exploit isoform-specific regulation in cardiac disease 25, 44, 47 may eventually permit the selective suppression of the ATRinduced I KAChC enhancement that helps to perpetuate AF. 4, 32 ATR-induced atrial hypocontractility associated with AF is an important contributor to thromboembolic complications. Exploration of the consequences of ATR-induced PKC isoform changes for atrial contractile function therefore may be interesting.
Potential Limitations
The mechanisms underlying tachycardia-induced PKC translocation to the membrane remain unclear and will require further investigation. Receptors for activated C-kinase constitute a family of membrane-associated PKC-anchoring proteins that are PKC isoform-specific. 48, 49 They may play a role in altered PKC isoform expression and localization. Voigt et al 10 found increased atrial PKC expression in AF patients, whereas we noted no change in total expression but increased relative membrane localization. This discrepancy could be attributable to technical differences (use of whole tissue in the Voigt study vs isolated cardiomyocytes in ours), species differences, and differences in the duration of atrial tachyarrhythmia, or in underlying heart disease. Increased membrane partitioning of PKC isoforms, commonly associated with their activation, is usually attributed to membrane translocation. Mechanistically, however, it could be attributable to translocation per se, enhanced degradation of cytosolic PKC, enhanced stability of membrane PKC, or even a localized posttranslational modification that alters antibody affinity.
In the present study, we investigated I KACh behavior in vitro, with conditions (ion concentrations, temperature, and so others) that are different from those in vivo. In vitro assessment was essential to probe the behavior of single I KACh channels and its response to pharmacological manipulation. Nevertheless, our data should be extrapolated with caution to in vivo conditions. We examined LA cells because of the evidence for a prominent role of LA sources for AF perpetuation. 50 It remains to be determined whether similar mechanisms operate in the right atrium and various discrete atrial structures. Such an analysis, although potentially interesting, is out of the scope of the present study.
We have not identified enhanced phosphorylation of specific sites through which PKC isoforms modulate I KACh in canine atrial cardiomyocytes. There are at least 12 PKC consensus sites on Kir3.1 and 3.4, 26 and PKCs could also be acting indirectly by phosphorylating Kir3.1/3.4-interacting proteins rather than channel proteins per se. Definitive identification of the PKC phosphorylation sites that modulate I KACh , particularly for the stimulatory effect of PKC, would be of great interest for future work.
Conclusions
We have examined mechanisms underlying enhanced I KAChC function in ATR at the single-channel level in cell-attached and cell-free membrane patches. Our results identify altered PKC isoform-dependent phosphorylation in ATR as an important contributor to I KACh activation in the absence of cholinergic agonists. Altered cPKC/nPKC regulation of I KACh may constitute a novel atrial-selective and pathologyselective target for AF therapy. 
Novelty and Significance
What is Known?
• Atrial fibrillation (AF) is the most common sustained cardiac rhythm disorder. It remodels atrial electric function in a way that promotes its own maintenance and causes increasing resistance to therapy. • An important component of AF-related remodeling is increased ligand-independent (constitutive) activity of a ligand-gated potassium channel that is normally operated by acetylcholine. Protein kinase C (PKC) modulates the activity of several ion channels.
What New Information Does This Article Contribute?
• Conventional (Ca 2ϩ -dependent) PKC isofroms inhibit, whereas the novel (Ca 2ϩ -independent) PKC isoforms enhance the activity of atrial acetylcholine-regulated potassium channels. • Rapid activation of atrial cardiomyocytes to mimic AF reduces the expression of the conventional PKC␣ isoform and enhances membrane localization of the novel PKC isoform, shifting the balance of PKC action toward channel activation. • Tachycardia-induced changes in PKC␣ isoform expression require cell Ca 2ϩ loading, likely via the Ca 2ϩ -dependent proteolytic enzyme calpain.
Atrial remodeling caused by AF is an important contributor to the pathophysiology of arrhythmia; however, the underlying mechanisms are poorly understood. We examined enhanced activity of the acetylcholine-regulated potassium channel (I KACh ) in the absence of agonist (constitutive activity), which is an important component of this remodeling. We show, for the first time to our knowledge, that the conventional (Ca 2ϩ -dependent) and the novel (Ca 2ϩ -independent) isoforms have opposite effects on I KACh , with conventional isoforms inhibiting and novel isoforms enhancing I KACh channel activity in isolated membrane patches. We found that PKC␣ is downregulated by the rapid cell-firing rates associated with AF, and that this effect is Ca 2ϩdependent. It is likely mediated by the Ca 2ϩ -dependent proteolytic enzyme, calpain. In contrast, PKC accumulates in the membranes of rapidly firing cells in a Ca 2ϩ -independent way. Thus, rapid cell-firing shifts the balance from the inhibitory conventional isoforms toward the stimulatory novel isoforms, thereby activating the channel. This knowledge helps in understanding the pathophysiology of AF and may allow development of novel therapeutic approaches.
